SP

Sudarshan Pharma Industries Ltd

Q2 FY27Chemicals & Petrochemicals

Sudarshan Pharma Industries Q2 Results 2026: PAT ₹8 Cr (+101% YoY)

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹217Cr
+28.5% YoY
+24.4% QoQ
Net profit
₹8Cr
+101% YoY
+38.7% QoQ
Margin
9.49%
+4 pp YoY
+0.4 pp QoQ

Sudarshan Pharma Industries Ltd Q2 FY27 key numbers

Revenue
Revenue from Operations for September 2026 quarter: ₹391.39 Cr.

As stated in Sudarshan Pharma Industries Ltd's Q2 FY27 investor presentation · published 6 Nov 2026. Reported figures, not investment advice.

Based on Sudarshan Pharma Industries Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹32
Market cap₹822 Cr
P/E28.3

The short version

Revenue from Operations for September 2026 quarter: ₹391.39 Cr (Page 41). For the quarter ending September 2026:.

From Sudarshan Pharma Industries Ltd's Q2 FY27 earnings-call transcript · updated 7 Nov 2026.

How did Sudarshan Pharma Industries' revenue grow in the September 2026 quarter?

  • Revenue from Operations for September 2026 quarter: ₹391.39 Cr (Page 41)
  • Revenue from Operations for September 2025 quarter: ₹314.13 Cr (Page 41)
  • Year-on-year growth: Approximately +24.7% (₹391.39 Cr vs ₹314.13 Cr)
  • Financial year revenue growth: FY26 ₹703.06 Cr vs FY25 ₹505.05 Cr (+39.2%) as per Page 42.

2 more points from Sudarshan Pharma Industries Ltd's call on revenue

Create a free account to keep reading this call

What happened to Sudarshan Pharma Industries' margins in Q2 FY27?

See what Sudarshan Pharma Industries Ltd said on profitability & margins — free account, 30 seconds.

What capex is Sudarshan Pharma Industries planning?

  • Setting up a manufacturing unit for critical APIs currently imported from China (Page 32).
  • Nutraceuticals Plant project:
  • Project cost: Rs. 2.5 Cr.
  • Machinery cost: Rs. 1.15 Cr.
  • Capsule and oral liquid manufacturing unit erected at Palghar (2021-2022 milestones, Page 9).
  • Acquired capex for Rs. 25.50 Cr. from Srigen Lifesciences Private Limited (2025-2026 milestones, Page 9).

2 more points from Sudarshan Pharma Industries Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Sudarshan Pharma Industries raising money or cutting debt?

See what Sudarshan Pharma Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Sudarshan Pharma Industries' order book?

See what Sudarshan Pharma Industries Ltd said on order book & pipeline — free account, 30 seconds.

Sudarshan Pharma Industries Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Sudarshan Pharma Industries Ltd Q2 FY27 results — key figures

Sudarshan Pharma Industries Ltd Q2 FY27 reported results vs Q2 FY26, ₹ crore
₹ CrQ2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue217169+28.5%174+24.4%
Operating profit (EBITDA)219+123.6%16+29.5%
Operating margin9.49%5.45%+4 pp9.12%+0.4 pp
Profit before tax114+155.3%8+44%
Net profit (PAT)84+101%6+38.7%
EPS (₹)0.320.17+88.2%0.23+39.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Chemicals & Petrochemicals

All Q2 FY27 results | Chemicals & Petrochemicals rankings

What Sudarshan Pharma's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sudarshan Pharma Industries Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sudarshan Pharma Industries Ltd Q2 FY27 results?

Sudarshan Pharma Industries reported net profit of ₹8 Cr (+101% YoY) on revenue of ₹217 Cr (+28.5% YoY) in Q2 FY27.

What is Sudarshan Pharma Industries Ltd share price analysis?

Sudarshan Pharma Industries Ltd currently shows a neutral. The stock trades at a P/E of 28.3 with a market cap of ₹822 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sudarshan Pharma Industries Ltd planning capital expenditure?

Setting up a manufacturing unit for critical APIs currently imported from China (Page 32).

Keep Sudarshan Pharma Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.